Literature DB >> 14733419

Calcitriol pulse therapy and histology of parathyroid glands in hemodialysis patients.

Carlo Lomonte1, Rocco Martino, Michele Selvaggiolo, Rosa Maria Bona, Francesco Cazzato, Rocco Milano, Giovanni Chiarulli, Carlo Basile.   

Abstract

BACKGROUND: Calcitriol pulse therapy (CPT) is considered the most appropriate treatment of secondary hyperparathyroidism (sHPTH). This treatment inhibits parathyroid hormone (PTH) synthesis and secretion, suppresses parathyroid cell proliferation and controls parathyroid gland growth. However, not much is known about the effect of such therapy on parathyroid morphology.
METHODS: To investigate this, we studied all first parathyroidectomies (PTx, either total or subtotal) effected in 30 hemodialysis (HD) patients referred to our surgery department by five regional dialysis units in 2000-2001. Six patients were excluded from the study because of either the persistence or the precocious relapse (in the 1st 6 months post-operation) of sHPTH. Twenty-four HD patients were considered eligible as four parathyroid glands were ablated in each patient; 96 glands were then examined histologically. The cohort consisted of 16 males and 8 females with a mean age of 54 +/- 13 SD yrs (range 20-73) and a dialysis duration of 142 +/- 71 months (range 14-289). Data concerning calcitriol treatment (doses, administration route and treatment duration) were collected for each patient. The patients were subdivided into two groups according to the treatment effected in the months preceding PTx: group A (n=13), treated by either intravenous (i.v.) (n=12) or per os (n=1) CPT, and group B (n=11), not treated at all with calcitriol or vitamin D sterols. Parathyroid gland morphology and the parenchymal cell distribution of the parathyroid glands were evaluated by a semiquantitative assessment. Serum intact PTH (iPTH), alkaline phosphatase (AP), calcium (Ca) and phosphate (P) levels were studied pre- and post-PTx.
RESULTS: Chief cells (CC) were found in all glands, either alone or associated with oxyphil cells (OC). OC were present in 13 of 24 patients (54%); however, it must be underlined that they were present 12 times in group A parathyroid glands (92%), and only once in group B (9%) (p<0.01). Nodular hyperplasia was found in 71% (17/24) of patients: 92% (12/13) in group A, and 45% (5/11) in group B (p<0.05). There were no significant differences in age, gender, dialysis duration, serum levels of iPTH, AP, Ca and P levels between the two groups.
CONCLUSIONS: There was a strong association between OC presence in parathyroid glands and CPT. Furthermore, nodular hyperplasia appeared to be associated significantly with CPT. There is still speculation regarding the meaning of these CPT effects on parathyroid gland histology and consequently on sHPTH pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14733419

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  4 in total

1.  Integrated transcriptomic and proteomic analyses for the characterization of parathyroid oxyphil cells in uremic patients.

Authors:  Jianping Mao; Huaizhou You; Mengjing Wang; Li Ni; Qian Zhang; Minmin Zhang; Jing Chen
Journal:  Amino Acids       Date:  2022-03-29       Impact factor: 3.520

2.  Differential gene expression by oxyphil and chief cells of human parathyroid glands.

Authors:  Cynthia S Ritter; Bruce H Haughey; Brent Miller; Alex J Brown
Journal:  J Clin Endocrinol Metab       Date:  2012-05-14       Impact factor: 5.958

3.  Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism?

Authors:  Carlo Lomonte; Luigi Vernaglione; Domenico Chimienti; Andrea Bruno; Savino Cocola; Annalisa Teutonico; Francesco Cazzato; Carlo Basile
Journal:  Clin J Am Soc Nephrol       Date:  2008-03-05       Impact factor: 8.237

4.  Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.

Authors:  Cai-Mei Zheng; Chia-Chao Wu; Chi-Feng Hung; Min-Tser Liao; Jia-Fwu Shyu; Yung-Ho Hsu; Chien-Lin Lu; Yuan-Hung Wang; Jing-Quan Zheng; Tian-Jong Chang; Yuh-Feng Lin; Kuo-Cheng Lu
Journal:  Nutrients       Date:  2018-02-10       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.